Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases-Reference-Cited by-同舟云学术

Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases

Published:2023-11 Issue:11 Volume:112 Page:2910-2920
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Yadav Rajbharan^ORCID,Sukumaran Siddharth,Lutman Jeff,Mitra Mayur S.^ORCID,Halpern Wendy,Sun Tianhe^ORCID,Setiadi A. Francesca,Neighbors Margaret^ORCID,Sheng X. Rebecca,Yip Victor,Shen Ben-Quan^ORCID,Liu Chang^ORCID,Han Lyrialle,Ovacik Ayse Meric,Wu Yan,Glickstein Sara,Kunder Rebecca,Arron Joseph R.^ORCID,Pan Lin,Kamath Amrita V.,Stefanich Eric G.

Funder

Genentech

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference45 articles.

1. Shared and distinct mechanisms of fibrosis;Distler;Nat Rev Rheumatol,2019

2. Transforming growth factor-beta. Major role in regulation of extracellular matrix;Roberts;Ann NY Acad Sci,1990

3. TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology;Morikawa;Cold Spring Harb Perspect Biol,2016

4. TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis;Sun;Sci Transl Med,2021

5. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients;Rice;J Clin Invest,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers;Rheumatology and Therapy;2024-04-25

2. Isoform-selective TGF-β3 inhibition for systemic sclerosis;Med;2024-02